Lonza Group AG stock (CH0013841017): New CEO and strategy update keep investors focused on turnaround

Lonza Group AG is pushing its multi?year transformation under a new CEO and updated 2024–2028 strategy. Recent guidance, portfolio moves and a continued focus on biologics manufacturing are in focus for investors watching the Swiss CDMO heavyweight.

Lonza Group AG is in the spotlight as it advances a multi?year transformation program under a new chief executive and a refreshed 2024–2028 strategy that aims to sharpen its focus on biologics and cell?and?gene therapies. The company has been reshaping its portfolio, updating mid?term financial targets and emphasizing disciplined capital allocation, according to a capital markets day presentation published on November 14, 2023, by Lonza.Lonza news as of 11/14/2023 These changes follow a challenging period around the exit of a large COVID?19 contract and mark a strategic reset for one of the leading global contract development and manufacturing organizations in healthcare.

In its strategic update, Lonza set out a framework for 2024–2028 that foresees mid? to high?single?digit average annual sales growth and a gradual improvement in core EBITDA margins, contingent on execution of growth projects and operational efficiency measures, according to its investor materials published the same day.Lonza investors as of 11/14/2023 The company also highlighted a broad investment program in biologics capacity that is expected to support pipeline demand from pharmaceutical and biotechnology customers worldwide, even as the broader CDMO sector adjusts after the pandemic demand surge.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Life sciences, contract development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Biopharmaceuticals, small molecules, capsules and consumer health ingredients
• Key revenue drivers: Biologics manufacturing services and small molecule contract manufacturing
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG operates as a global contract development and manufacturing organization focused on helping pharmaceutical and biotechnology companies develop and produce active ingredients and finished dosage forms. The group generates most of its revenue from fee?for?service contracts, under which it provides development, clinical and commercial manufacturing capabilities for complex biologics, small molecules and cell?and?gene therapies, according to its 2023 annual report published on January 24, 2024.Lonza investors as of 01/24/2024

The company’s activities are organized into divisions that address different technology platforms, including large?scale mammalian and microbial biologics, cell?and?gene technologies and small molecule manufacturing, as well as capsules and health ingredients for the nutrition and consumer health markets. This diversified platform allows Lonza to serve customers across the drug lifecycle, from early development to commercial supply, while spreading its exposure across therapeutic areas and modalities, according to its strategic overview in 2023.Lonza news as of 11/14/2023

Unlike fully integrated pharmaceutical companies, Lonza does not typically own the intellectual property for the drugs it manufactures. Instead, it earns revenue from long?term manufacturing and development agreements that can involve multi?year commitments and capacity reservations from its clients. This model can provide a degree of earnings visibility when contracts are long?dated, but it also exposes the company to project timing shifts and contract changes, as seen when it exited a major COVID?19 vaccine manufacturing agreement in 2023, according to disclosures in its 2023 annual report.Lonza investors as of 01/24/2024

Main revenue and product drivers for Lonza Group AG

The biologics segment is a key growth engine for Lonza, contributing a substantial share of group sales. The company has made significant capital investments in large?scale bioreactor capacity in Europe, the United States and Asia to meet rising demand for monoclonal antibodies and other biologic therapies, according to its strategic update and capital expenditure plans released in November 2023.Lonza news as of 11/14/2023 These investments are aimed at securing long?term supply partnerships with big pharma and biotechnology customers that rely on external manufacturing to support their pipelines.

Another important contributor is small molecule contract manufacturing, where Lonza offers active pharmaceutical ingredient synthesis and finished dosage manufacturing. This business benefits from customers seeking to outsource complex chemical processes and regulatory?compliant production. Demand trends in small molecules can be more stable than in some emerging modalities, which helps balance the group’s exposure to newer technologies such as cell?and?gene therapies, according to management commentary in its 2023 annual report.Lonza investors as of 01/24/2024

Beyond pharmaceuticals, Lonza’s capsules and health ingredients unit supplies hard capsules, dosage technologies and nutritional ingredients to customers in consumer health, over?the?counter medicines and dietary supplements. While this segment generally has lower margins than biologics, it provides a diversified revenue stream and exposure to consumer health trends, according to the 2023 annual report.Lonza investors as of 01/24/2024 The combination of high?growth biologics, established small molecule manufacturing and consumer?facing health products forms the backbone of Lonza’s revenue profile.

Conclusion

Lonza Group AG is managing a strategic transition after its pandemic?era peak, focusing on core biologics, small molecules and consumer health while executing a multi?year investment program. The updated 2024–2028 framework outlines moderate growth and margin ambitions, but outcomes will depend on contract wins, project execution and capacity utilization. For US investors following global healthcare and CDMO trends, the Swiss?listed stock offers an example of how large contract manufacturers are adapting in a post?COVID environment, with both opportunities from pipeline outsourcing and risks linked to project dynamics and capital intensity.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.